Published in Health Business Week, January 12th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at NicOx.
Report 1: NicOx (NICOX) announced that the United States Food and Drug Administration (FDA) has stated that based on the information available at this time, a large clinical cardiovascular outcomes study would not be required at the time of submission of a New Drug Application (NDA) for naproxcinod (HCT 3012).
Naproxcinod is in phase III clinical development for the treatment of the signs and symptoms of osteoarthritis.
Report 2: NicOx S.A. has completed subject...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.